Breaking News
July 21, 2018 - Researchers identify subtypes of retinal ganglion cells using single-cell RNA sequencing
July 21, 2018 - Study uncovers opportunities to reduce death by suicide among cancer patients
July 21, 2018 - Genetic sequencing reveals new clues to aggressiveness of prostate cancer
July 21, 2018 - BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
July 21, 2018 - First major study comparing robotic to open surgery published in The Lancet
July 21, 2018 - ADHD medications may fail to improve cognition in healthy college students, study shows
July 21, 2018 - Intervention program that includes a personalized app could benefit teens with suicidal thoughts
July 21, 2018 - Researchers identify new compound that protects against neurodegeneration
July 21, 2018 - Gene therapy may hold potential to treat people with spinal cord injuries
July 21, 2018 - FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 21, 2018 - Surgeons have substantial impact on genetic testing in breast cancer patients who need it
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Researchers study efficacy and safety of new treatment for OUD
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Study examines effects of a two-day intermittent calorie restriction diet for patients with type 2 diabetes
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
July 21, 2018 - Researchers develop new way to uncover hidden breast cancer tumors
July 21, 2018 - FDA approves first drug for treatment of adult AML patients with specific genetic mutation
July 21, 2018 - Top AI companies join hands to discover novel drugs for DMD
July 21, 2018 - Ferring announces FDA approval of ZOMACTON for injection in four new pediatric indications
July 20, 2018 - Researchers design proteins that can self-assemble into complex structures
July 20, 2018 - AVITA Medical expands management team to support launch of RECELL device to treat burns
July 20, 2018 - FDA Approves Tibsovo (ivosidenib) for Relapsed or Refractory Acute Myeloid Leukemia with an IDH1 Mutation
July 20, 2018 - Developmental screening and surveillance rates remain low, new study suggests
July 20, 2018 - TGen opens tissue donation portal to advance DIPG research
July 20, 2018 - Health impact of highly processed summertime staples
July 20, 2018 - Exergaming can improve health in overweight and obese children, study shows
July 20, 2018 - Postmenopausal factors may impact heart-protective qualities of ‘good cholesterol’
July 20, 2018 - MRI and blood test combination results in improved prostate cancer diagnosis
July 20, 2018 - Update Health Professional and Consumer on Recent Recalled Products
July 20, 2018 - Researchers trace Parkinson’s damage in the heart
July 20, 2018 - Wearable device designed to measure cortisol in sweat
July 20, 2018 - Scientists demonstrate a new regulation mechanism for skeletal muscles
July 20, 2018 - Exposure to mobile phone radiation may negatively impact memory performance in adolescents
July 20, 2018 - SUSU scientists find alternative method to treat post-traumatic stress disorder syndrome
July 20, 2018 - Gestational diabetes may increase offspring’s heart disease risk
July 20, 2018 - New vaccine could protect unborn babies from Zika virus
July 20, 2018 - Researchers find high mercury and methylmercury concentrations in traditional Tibetan medicine
July 20, 2018 - Brief Safety Plan Intervention in ER Can Cut Suicidal Behavior
July 20, 2018 - The Mount Sinai Hospital receives accreditation as geriatric emergency department
July 20, 2018 - Toward a better understanding of Parkinson’s disease
July 20, 2018 - Med school communications office wins four national awards | News Center
July 20, 2018 - Professional baseball players with faster hand-eye coordination may have better batting performance
July 20, 2018 - Study looks into mechanisms that control sleep and wakefulness
July 20, 2018 - Scientists identify melanoma biomarkers that could help tailor immunotherapy treatments
July 20, 2018 - Research reveals long-term efficacy of drug used to treat common cause of kidney failure
July 20, 2018 - Timing of dinner associated with breast and prostate cancer risks
July 20, 2018 - Health Tip: Performing the Heimlich Maneuver
July 20, 2018 - Nearly all adolescents have eating, activity or weight-related issues
July 20, 2018 - Sage launches new web-based tool that helps explore curated genomic analyses of Alzheimer’s
July 20, 2018 - High-performance porous polymeric material for chromatography applications
July 20, 2018 - New molecule shows great promise for future treatment of many cancers
July 20, 2018 - New research project investigates alternative treatments for eye infections
July 20, 2018 - Immune T cells are built to react as fast as possible, shows study
July 20, 2018 - ZHX2 protein could offer a new treatment strategy for kidney cancer
July 20, 2018 - EKF’s Quo-Lab POC HbA1c analyzer meets international quality targets for diabetes testing
July 20, 2018 - Health burdens of very high risk drinking are potentially large, study reveals
Some other Win for CAR-T Treatment (CME/CE)

Some other Win for CAR-T Treatment (CME/CE)

image_pdfDownload PDFimage_print

Motion Issues

  • Observe that this learn about used to be printed as an summary and introduced at a convention. Those knowledge and conclusions must be regarded as to be initial till printed in a peer-reviewed magazine.
  • Observe that this out of control trial of CAR-T cellular remedy for relapsed CNS ALL confirmed dramatic efficacy in the case of remission and sturdy remission.
  • Whilst ALL is imminently treatable on first presentation, remedy good fortune after a relapse is unusual, making this remedy a possible paradigm shift.

MONTREAL – The investigational chimeric antigen receptor T cellular (CAR-T) remedy CTL019 triggered “potent and sturdy responses” in youngsters with central apprehensive gadget (CNS) involvement in relapsing/refractory acute lymphoblastic leukemia (ALL), a researcher reported right here.

In a secondary research of the segment I/IIa CHP 959 learn about, having a look most effective at youngsters with CNS involvement, 71% stay in whole remission a mean of 11 months after the remedy, reported Mala Talekar, MD, from Youngsters’s Medical institution of Philadelphia.

Presenting the findings at the yearly assembly of the American Society of Pediatric Hematology/Oncology right here, Talekar stated the “exceptional milestone” underscores the potential of CTL019, a Novartis product that lately won “leap forward” designation and is present process precedence evaluate by means of the FDA.

“Everyone is aware of that we do a perfect task treating newly identified instances of ALL, same old chance, top chance, or any chance, however in the case of first relapse the curve principally plummets down,” stated Talekar. “Our easiest survival charges in the beginning relapse fall between a depressing 20%-60%, and as soon as a kid relapses a 2nd time they fall all the way down to the 10%-20% vary.”

The CHP 959 learn about incorporated 60 youngsters with relapse/refractory CD19-positive ALL who underwent CTL019 CAR-T-cell remedy and had been evaluated each Three months for relapse in bone marrow and cerebrospinal fluid (CSF).

At 12-months post-infusion, total survival used to be 79%, “or even at 24 months total survival is someplace within the vary of 65%, which is superior should you believe the inhabitants this is receiving this remedy,” stated Talekar. “This inhabitants is youngsters who’ve had two or extra relapses or had been refractory to remedy, with the bulk being refractory to more than one remedies.”

General, the learn about confirmed a 93% whole remission fee at day 28, with 100% of sufferers attaining CNS remission. Cytokine unencumber syndrome used to be observed in 88% of sufferers however used to be most effective serious in 27%, she reported.

The researchers then made up our minds to concentrate on the subset of 17 sufferers whose indication for the remedy used to be CNS relapse.

“We outlined CNS relapse as CNS3 by means of lumbar puncture or mind or ocular involvement on imaging.”

The choice of relapses on this subgroup ranged as much as seven, with 10 sufferers having remoted CNS relapse and 7 with mixed bone marrow/CNS relapse.

“Once we first began enrolling, our eligibility standards strictly specified both CNS 1 illness or CNS 2. We weren’t enrolling CNS Three sufferers as a result of we weren’t certain whether or not it used to be going to be efficacious or what the toxicities had been going to be. However as we noticed the trial evolving and that the CTL019 cells had been trafficking to the CSF we made up our minds to sign up CNS3 sufferers as smartly,” she defined. They enrolled 3.

At day 28 of follow-up, 16 of the 17 sufferers had been staged as CNS1 in keeping with CSF. Some of the Three sufferers who had been CNS3 prior to remedy, one used to be now not evaluable because of fast development of bone marrow illness, one used to be in whole remission, and the opposite had preliminary “pseudo development” however therefore whole remission at 3 months.

Of the 12 sufferers who stay in whole remission at 2-Three months post-infusion, 5 had remoted relapses in marrow however all had been CNS unfavourable, stated Talekar.

Neurotoxicity with this remedy “is a sizzling matter at the moment,” she added. “One would assume that sufferers who’ve CNS illness will be the ones who had probably the most toxicity however that didn’t appear to be the case.”

Some of the 17 CNS sufferers the velocity of Grade Three encephalopathy used to be 18% in comparison to a 28% fee within the non-CNS sufferers, and whilst one affected person in each and every cohort had a grade 2 seizure, there used to be additionally two extra sufferers with Grade Three and four seizures within the non-CNS staff as opposed to none within the CNS staff.

“We did see all kinds of neurotoxicity signs starting from agitation, ataxia, dizziness, confusion, trigeminal neuralgia, speech disturbance and imaginative and prescient disturbance … however the essential factor to notice used to be all sufferers had been again to their neurologic baseline by means of month Three,” she concluded.

Talekar declared she had no related monetary pursuits.

  • Reviewed by means of
    F. Perry Wilson, MD, MSCE Assistant Professor, Phase of Nephrology, Yale Faculty of Medication and Dorothy Caputo, MA, BSN, RN, Nurse Planner


Tagged with:

About author

Related Articles